Pulmonale Hypertension beim Hund: Ursachen, Therapie und Prognose

Dyspnoe, Synkope, Kongestion, unspezifische Symptome – Diagnostik und Therapie bei pulmonaler Hypertension sind komplex. Die breite Verfügbarkeit von Echokardiografie zur Druckbestimmung gestattet die Diagnosestellung. Zahlreiche Ursachen sind möglich und die Therapie ist eine Herausforderung.

• Literatur

• 1 Schober KE, Baade H. Doppler echocardiographic prediction of pulmonary hypertension in West Highland white terriers with chronic pulmonary disease. J Vet Intern Med 2006; 20: 912-920
• 2 McLaughlin VV, Archer SL, Badesch DB. et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119 (16) 2250-2294
• 3 Simonneau G, Gatzoulis MA, Adatia I. et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: 34-41
• 4 Johnson L, Boon J, Orton EC. Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992–1996. J Vet Intern Med 1999; 13: 440-447
• 5 Pyle RL, Abbott J, MacLean H. Pulmonary hypertension and cardiovascular sequelae in 54 dogs. Intern J Appl Res Vet Med 2004; 2 (02) 99-109
• 6 Glaus TM, Soldati G, Maurer R. et al. Clinical and pathological characterisation of primary pulmonary hypertension in a dog. Vet Rec 2004; 154: 786-789
• 7 Zabka TS, Campbell FE, Wilson DW. Pulmonary arteriopathy and idiopathic pulmonary arterial hypertension in six dogs. Vet Pathol 2006; 43: 510-522
• 8 Jenkins TL, Jennings RN. Pulmonary capillary hemangiomatosis and hypertrophic cardiomyopathy in a Persian cat. J Vet Diagn Invest 2017; 29: 900-903
• 9 Williams K, Andrie K, Cartoceti A. et al. Pulmonary veno-occlusive disease: a newly recognized cause of severe pulmonary hypertension in dogs. Vet Pathol 2016; 53 (04) 813-822
• 10 Stepien RL. Pulmonary arterial hypertension secondary to chronic left-sided cardiac dysfunction in dogs. J Small Anim Pract 2009; 50 (01) 34-43
• 11 Serres FJ, Chetboul V, Tissier R. et al. Doppler echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001–2005). J Am Vet Med Assoc 2016; 229 (11) 1772-1778
• 12 Serres F, Chetboul V, Gouni V. et al. Diagnostic value of echo‐Doppler and tissue Doppler imaging in dogs with pulmonary arterial hypertension. J Vet Intern Med 2007; 21 (06) 1280-1289
• 13 Borgarelli M, Zini E, DʼAgnolo G. et al. Comparison of primary mitral valve disease in German Shepherd dogs and in small breeds. J Vet Cardiol 2004; 6 (02) 27-34
• 14 Johnson LR, Lappin MR, Baker DC. Pulmonary thromboembolism in 29 dogs: 1985–1995. J Vet Intern Med 1999; 13 (04) 338-345
• 15 Johnson RJ. Pulmonary hypertension. In: Luis Fuentes V, Johnson LR, Dennis S. eds. BSAVA Manual of Canine and Feline Cardiorespiratory Medicine. 2nd ed.. Gloucester: British Small Animal Veterinary Association; 2010: 264-267
• 16 Atkins C, Bonagura J, Ettinger S. et al. Guidelines fort he diagnosis and treatment of canine chronic valve disease. J Vet Intern Med 2009; 23 (06) 1142-1150
• 17 Bach JF, Rozanski EA, MacGregor J. et al. Retrospective evaluation of sildenafil citrate as a therapy for pulmonary hypertension in dogs. J Vet Intern Med 2006; 20: 1132-1135
• 18 Kellum HB, Stepien RL. Sildenafil citrate therapy in 22 dogs with pulmonary hypertension. J Vet Intern Med 2007; 21: 1258-1264
• 19 Serres F, Nicolle AP, Tissier R. et al. Efficacy of oral tadalafil, a new long-acting phosphodiesterase-5 inhibitor, for the short-term treatment of pulmonary arterial hypertension in a dog. J Vet Med A Physiol Pathol Clin Med 2006; 53 (03) 129-133
• 20 Atkinson KJ, Fine DM, Thombs LA. et al. Evaluation of pimobendan and N-terminal probrain natriuretiv peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. J Vet Intern Med 2009; 23 (06) 1190-1196
• 21 Murphy LA, Russell N, Bianco D. et al. Retrospective evaluation of pimobendan and sildenafil therapy for severe pulmonary hypertension due to lung disease and hypoxia in 28 dogs (2007–2013). Vet Med Sci 2017; 3 (02) 99-106
• 22 Borgeat K, Sudunagunta S, Kaye B. et al. Retrospective evaluation of moderate-to-severe pulmonary hypertension in dogs naturally infected with Angiostrongylus vasorum. J Small Anim Pract 2015; 56 (03) 196-202
• 23 Borgarelli M, Abbott J, Braz-Ruivo L. et al. Prevalence and prognostic importance of pulmonary hypertension in dogs with myxomatous mitral valve disease. J Vet Intern Med 2015; 29 (02) 569-574